Privately negotiated exchange of $20.0 million principal of 1.25% Convertible Senior Notes due 2027 for $20.0 million of 4.875% Convertible Senior Notes due 2030 and approximately $2.2 million in cash.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Michael Severino
Also a director
Chief Executive Officer
Title from the Form 8-K dated Jul 28, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Ryan H. Wong
Executive Vice President, Chief Financial Officer
|
47 |
Since 2025
1 year
|
Not stated | $3,211,867 | |
|
Ian M. Estepan
President, Chief Operating Officer
|
50 |
Since 2025
1 year
|
2015 | $4,444,392 | |
|
Cristin L. Rothfuss
Executive Vice President, General Counsel
|
58 |
Since 2024
2 years
|
2018 | $4,233,623 | |
|
Louise Rodino-Klapac
President, R&D and Tech Ops
Title from the Form 4 dated Sep 4, 2026
|
48 | Not stated | 2018 | $4,456,270 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 24, 2026 · updated by the 8-K of Jul 27, 2026
| Director | Age | On board | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|
|
M. Kathleen Behrens, Ph.D.
Board chair
|
73 |
2009
17 years
|
Audit Committee · Chair
|
MiMedx Group Inc. | $603,923 | |
|
Douglas S. Ingram
CEO
|
63 |
2017
9 years
|
None stated | Relay Therapeutics | Paid as CEO | |
|
Michael Severino
Joined Jul 28, 2026
CEO
|
- | - | - | - | Paid as CEO | |
|
Hans Wigzell, M.D., Ph.D.
|
87 |
2010
16 years
|
Nominating and Corporate Governance Committee
Research and Development Committee · Chair
|
RaySearch Laboratories AB | $562,466 | |
|
Kathryn J. Boor, Ph.D.
|
67 |
2022
4 years
|
Compensation Committee
|
Seneca Foods Corporation | $552,466 | |
|
Michael Chambers
|
51 |
2022
4 years
|
Research and Development Committee
|
Calviri Inc | $544,466 | |
|
Deirdre Connelly
|
65 |
2024
2 years
|
Compensation Committee · Chair
Nominating and Corporate Governance Committee
|
Macy’s Corporation, Lincoln Financial Group, Genmab A/B | $558,153 | |
|
Richard J. Barry
|
67 |
2015
11 years
|
Nominating and Corporate Governance Committee · Chair
|
Filana Therapeutics, Inc. | $577,279 | |
|
Stephen L. Mayo, Ph.D.
|
64 |
2021
5 years
|
Audit Committee
Research and Development Committee
|
Merck, Allogene Therapeutics | $556,966 | |
|
Claude Nicaise, M.D.
|
73 |
2015
11 years
|
Compensation Committee
Research and Development Committee
|
Minoryx, Gain Therapeutics, Chemomab, Filana Therapeutics, Inc. | $554,466 |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Privately negotiated exchange of $20.0 million principal of 1.25% Convertible Senior Notes due 2027 for $20.0 million of 4.875% Convertible Senior Notes due 2030 and approximately $2.2 million in cash.
Loading...